Brainstorm Cell Therapeutics | BCLI

Brainstorm Cell Therapeutics traded at $1.82 this Tuesday January 31st, increasing $0.08 or 4.30 percent since the previous trading session. Looking back, over the last four weeks, Brainstorm Cell Therapeutics gained 8.98 percent. Over the last 12 months, its price fell by 43.48 percent. Looking ahead, we forecast Brainstorm Cell Therapeutics to be priced at 1.47 by the end of this quarter and at 1.33 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Adamis Pharmaceuticals 0.20 0.01 2.77% -68.01%
Brainstorm Cell Therapeutics 1.82 0.08 4.30% -43.48%
Biogen 290.90 4.96 1.73% 26.83%
Cytokinetics 42.48 1.42 3.46% 26.54%
Gilead Sciences 83.94 0.59 0.71% 22.59%
Halozyme Therapeutics 51.77 0.65 1.27% 47.33%
Aceragen Inc 4.69 -0.32 -6.29% -54.03%
Mesoblast Ltd 1.04 0.09 9.47% -10.34%

Indexes Price Day Year
USND 11585 190.74 1.67% -19.25%

Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on development of cellular therapies for the treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD) and other neurodegenerative diseases. The Company offers its services through NurOwn platform. Its BrainStorm Cell Therapeutics Ltd. (Israeli Subsidiary) holds rights to commercialize the technology, NurOwn. Its NurOwn platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.